Full-Time

Packaging Operator

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Plattsburgh, NY, USA

In Person

Category
Operations & Logistics (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets

Get referred to Viatris

See people who can refer or advise you

Requirements
  • HS diploma
  • Minimum of two years of experience is required. However, a combination of experience and/or education will be taken into consideration.
  • Must possess good mechanical, communication, time management, organizational, interpersonal, and writing skills, and computer skills including Microsoft Word and Excel and Lotus Notes.
  • Ability to lift up to 50 pounds.
  • Ability to stoop, climb ladders, or stairs, stand or sit for extended periods of time.
  • Ability to wear a respirator.
  • Ability to hear an alarm.
  • Ability to identify small defects.
  • Ability to distinguish between colors.
Responsibilities
  • Visually inspect the product during operation, observe equipment and process for proper operation, seek maintenance assistance for problems and recommend improvements.
  • Assist with the set up and running of Production equipment.
  • Prepare and clean manufacturing rooms and equipment for inspection as required and keep work area in a clean and orderly condition.
  • Ensure all products are properly labeled and stored.
  • Document material runs via Batch Production Records, In-Process Sheets, Logbooks, and Time Sheets.
  • Assist in training new personnel in the manufacturing operation as directed by the supervisor or manager.
  • Perform calibration on scales, line meters, coating ovens, micrometers, etc. as instructed.
  • Coordinate the work of other Operators and acts as a backup to Senior Operator as directed by the supervisor or manager.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Access-driven medicines support recurring demand in emerging and developed markets.[5]
  • Complex generics and biosimilars improve mix versus plain commodity generics.[5]
  • The July 2026 yen term loan adds liquidity and refinancing flexibility.[1]

What critics are saying

  • Generic pricing pressure from Teva and Sandoz compresses margins quickly.[5]
  • Debt refinancing and covenant compliance constrain capital allocation and dividend capacity.[1]
  • Biosimilar competition from Biocon Biologics threatens Semglee-related growth.[5]

What makes Viatris unique

  • Viatris combines Mylan and Upjohn, bridging generics and branded medicines.[1]
  • It sells medicines across more than 165 countries and territories.[11]
  • Its portfolio spans branded, generic, complex generic, and biosimilar products.[7]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.